Gold Royalty Corp. shares rise 1.74% intraday after Royalty Pharma's acquisition of royalty interest in Amgen's Imdelltra.

Gold Royalty Corp. rose 1.74% intraday, with Royalty Pharma acquiring a royalty interest in Amgen's Imdelltra, a first-in-class immunotherapy for extensive-stage small cell lung cancer. The deal includes an upfront payment of $885 million and an option for BeOne Medicines to sell additional royalties for up to $65 million within the next 12 months. This acquisition aligns with Royalty Pharma's strategy of investing in innovative biopharmaceutical products, potentially driving future revenue growth.